A small clinical trial is giving hope to a closer cure for cancer. Every patient treated for rectal cancer with an experimental immunotherapy drug recently went into remission. !4 paitients were treated. All had stage 2 or 3 ectal adenocarcinoma (meaning the cancer had reached the lymph nodes but hadn't metastasized) with a specific mutation that's particularly sensitive to chemotherapy. They received the monoclonal antibody dostarlimab intravenously every three weeks for six months, a total of nine cycles. According to the study that was published in the New England Journal of Medicine by researchers at New York City’s Memorial Sloan Kettering Cancer Center (MSK), the rectal cancer tumors vanished for all 14 patients who completed treatment — a full clinical remission.
All 14 patients who were given the new drug, dostarlimab, were found after six months to have no trace of cancer. Researchers at Memorial Sloan Kettering cancer center in New York could find no sign of the disease through physical examination, endoscopies, MRIs or other scans.